We are live on ! Find out more

TEM

Tempus AI

TEM

Market cap $12.8B

70.69 USD

+2.21

3.23%

At close Updated Aug 27, 4:00 PM EDT

Pre-market

After hours

70.68

-0.01

0.01%

1 day

3.23%

5 days

7.76%

1 month

64.74%

3 months

49.86%

6 months

32.75%

Year to date

13.36%

1 year

-3.47%

5 years

75.63%

10 years

75.63%

About: Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.

Employees: 3,800

Healthcare Health Information Services

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 37.1%

Neutral 51.4%

Negative 11.4%

Top Performing Leveraged/Inverse ETFs: 08/23/2026

Top Performing Leveraged/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.

Top Performing Leveraged/Inverse ETFs: 08/23/2026

What's Going On With Tempus AI Stock on Monday?

Tempus AI Inc (NASDAQ:TEM) stock is trading lower on Monday as the stock is pulling back from an approximately 20% surge over the last week.

What's Going On With Tempus AI Stock on Monday?

Zacks Investment Research

Best-Performing Leveraged ETF Areas of Last Week

These leveraged ETFs surged last week as biotech, AI, crypto and Bitcoin-linked stocks rallied despite rising Treasury yields.

Best-Performing Leveraged ETF Areas of Last Week

Tempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGs

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Tempus ECG-PH (pulmonary hypertension), an AI-enabled software device that analyzes standard 12-lead electrocardiograms (ECGs) for signs associated with pulmonary hypertension. Tempus ECG-PH is the third FDA-cleared device in Tempus' growing cardiovascular portfolio, expanding the company's suite of next-generation AI products aimed at ide.

Tempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGs

The Motley Fool

Why Tempus AI Skyrocketed This Week

Tempus AI stock surged this week after Merck and Moderna published encouraging trial results for a cancer treatment. A company that Tempus AI is acquiring provided technologies that aided the development of Merck and Moderna's cancer vaccine.

Why Tempus AI Skyrocketed This Week

Tempus AI: Winning With Precision Medicine

Tempus AI, Inc. made a timely move to acquire the Personalis cancer monitoring tests to advance AI-driven precision medicine. Recent cancer vaccine developments from Merck and Moderna reinforce the strategic relevance and growth runway for TEM's platform. The company already had strong momentum with higher test ASPs, with the cancer tests a huge bonus.

Tempus AI: Winning With Precision Medicine

The Motley Fool

A Tempus AI Director Sold Stock Four Days Before a 24% Rally. Here's What to Know

The transaction involved 3,000 shares with a value of $161,700 on August 14. The sale reduced West's direct equity position by 8%.

A Tempus AI Director Sold Stock Four Days Before a 24% Rally. Here's What to Know

The Motley Fool

Is Tempus AI Stock a Buy After Its 75% Rally? Here's What to Know as the Firm's Legal Chief Files a Trade

Polovin executed the sale of 30,075 shares between August 18 and August 19, generating approximately $1.5 million in proceeds. The transaction was non-discretionary and performed to satisfy statutory tax withholding obligations following the vesting of restricted stock units.

Is Tempus AI Stock a Buy After Its 75% Rally? Here's What to Know as the Firm's Legal Chief Files a Trade

The Motley Fool

Tempus AI's Accounting Chief Just Reported an Insider Transaction. Here's What Long-Term Investors Should Know

These 6,175 shares were disposed of at a weighted average price of $49.61 per share, for a total transaction value of $306,342. The transaction was a "sell to cover" event executed to satisfy statutory tax withholding obligations following the vesting of restricted stock units.

Tempus AI's Accounting Chief Just Reported an Insider Transaction. Here's What Long-Term Investors Should Know

The Motley Fool

What to Know About the CFO of Tempus AI's Latest Insider Transaction Filing

The transaction involved 48,842 shares with an estimated value of about $2.7 million. This was a non-discretionary transaction executed to cover tax withholding obligations associated with the vesting of restricted stock units.

What to Know About the CFO of Tempus AI's Latest Insider Transaction Filing

See News Rankings

Price charts implemented using Lightweight Charts™